Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Dermatologic 3Other hematologic neoplasm 2Gynecologic 2Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Melanoma 3Neoplasms 1Neoplasm Metastasis 1

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × denileukin diftitox × Dermatologic × Clear all
NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Eisai Inc.

Phase 2 Completed
75 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

NCT00515528 2021-01-26

Vaccination Plus Ontak in Patients With Metastatic Melanoma

University of Chicago

Phase 2 Terminated
17 enrolled 7 charts
Dermatologic

Melanoma

NCT00299689 2014-09-05

Phase II Trial of Ontak With Metastatic Melanoma

James Graham Brown Cancer Center

Phase 2 Completed
69 enrolled 3 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡